leisure time -WSS

leisure time

author：explore 2025-09-28 02:30:12 - browse：43245

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Stigma and the return of syphilis

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Parkinson’s finding may lead to tests and, someday, treatments

Latest bird flu infection made farmworker sicker than earlier cases

Research misconduct: Proposed new rules face resistance

Scientists successfully use ultrasound imaging to map brain activity

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

Prosthetic arm enables patients to feel the objects they grip

In Memoriam: Notable people who died in 2023

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Anesthesiologist group: stop taking Ozempic before surgery

Dark money group runs ads on China biotech bill

ChatGPT in medicine: STAT answers readers' burning questions

Why doctors need education on FDA device approval process

How to save PrEP access — and even expand it

Childbirth

entertainment

Heat waves linked to early deliveries, preterm births in new study

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Report: NIH

Focused ultrasound for uterine fibroids: an uphill battle

Copay coupons to count toward deductibles, after Biden court move

eGenesis tests gene

explore

entertainment

entertainment

Wikipedia